The final decision was due to be published on the NICE website on 31 October and would have rejected ocrelizumab as an NHS treatment for primary progressive MS on the grounds of cost effectiveness.
The MS Trust now understands that this final decision has been postponed while further discussions take place between the drug company and NHS England. We welcome this move as it demonstrates a willingness on both sides to engage further in the debate around this drug which could have substantial impact on the lives of people with primary progressive MS.
No timeframes have yet been published, and the outcome is obviously unknown, but we will continue to campaign for equitable access to effective care options for everyone living with MS. Similarly we will continue to update you as and when further information becomes available following the NICE announcement.
Access to ocrelizumab for people living with PPMS would be a very welcome outcome to this further review, but we recognise that there are many factors which can influence the final decision. It is not yet clear how long, or what process will need to be followed, but it appears that access to a treatment which can slow down the progression of MS may have moved a step closer.
- David Martin, Chief Executive, MS Trust
The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.
Roxy's journey to diagnosis
16/05/2022 - 00:00
Roxy talks about her MS journey and the importance of sharing her own experiences to ensure that others don’t face the same challenges when receiving a diagnosis.
Lis' MS journey: one woman and her bike
04/05/2022 - 00:00
In May 2022, Lis will be heading off on her 5,000 mile cycling challenge. She shares how the idea came about and discusses why the support of the MS Trust was invaluable following a multiple sclerosis diagnosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.